About ACell
ACell is a company based in Lafayette (United States) founded in 1999 was acquired by Integra LifeSciences in December 2020. ACell has raised $8.7 million across 1 funding round from investors including Integra LifeSciences. The company has 398 employees as of December 31, 2022. ACell operates in a competitive market with competitors including Kerecis, Humacyte, Kitotech Medical, microMend and CUTISS, among others.
- Headquarter Lafayette, United States
- Employees 398 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name A Cell Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$8.7 M (USD)
in 1 rounds
-
Latest Funding Round
$8.7 M (USD), Series A
Apr 22, 2011
- Investors
-
Employee Count
398
as on Dec 31, 2022
-
Acquired by
Integra LifeSciences
(Dec 16, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of ACell
ACell has successfully raised a total of $8.7M through 1 strategic funding round. The most recent funding activity was a Series A round of $8.7 million completed in April 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ACell
ACell has secured backing from 1 investor. Prominent investors backing the company include Integra LifeSciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Diversified medical devices are developed for healthcare applications.
|
Locked | Locked | Locked |
Investor details for ACell
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ACell
Investment portfolio details for ACell
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ACell
Detailed financials for ACell
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Acell Comparisons
Peer comparison for ACell
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ACell
ACell operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Kerecis, Humacyte, Kitotech Medical, microMend and CUTISS, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Fish-skin acellular dermal matrix technology is provided for wound treatments.
|
|
| Locked | Locked | Locked |
Human tissue-based products are developed for vascular disease applications.
|
|
| Locked | Locked | Locked |
Developer of a device to close wounds, lacerations, and surgical incisions
|
|
| Locked | Locked | Locked |
Solutions for treating dermatological disorders are provided by microMend.
|
|
| Locked | Locked | Locked |
Personalized skin tissue therapy is developed by CUTISS for surgeries.
|
|
| Locked | Locked | Locked |
Developer of biodegradable temporising matrix for treating traumatic wounds
|
Detailed competitors of ACell
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Acell
Complete news archive for ACell
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ACell
ACell was founded in 1999 and raised its 1st funding round 12 years after it was founded.
ACell is headquartered in Lafayette, United States. It is registered at Lafayette, Louisiana, United States.
ACell is a funded company, having raised a total of $8.7M across 1 funding round to date.
As of Dec 31, 2022, the latest employee count at ACell is 398.
ACell was founded in 1999 as a regenerative medicine company focused on tissue repair and remodeling. Extracellular Matrix (ECM) technology, based on the Urinary Bladder Matrix (UBM) platform, is utilized to create products such as Wound Matrix, Burn Matrix, MicroMatrix, Pelvic Floor Matrix, and Surgical Matrix. Operations include development and manufacturing, with headquarters in Columbia and a facility in Lafayette, United States.
ACell has 1 investor. Key investors include Integra LifeSciences.